The role of dopamine agonists in early Parkinson's disease

Neurology ◽  
1997 ◽  
Vol 49 (Issue 1, Supplement 1) ◽  
pp. S34-S48 ◽  
Author(s):  
R. L. Watts
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Agonists ◽  
Early Parkinson’S Disease

Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis

2009 ◽  
Vol 15 (4) ◽  
pp. 287-294 ◽  
Author(s):  
William L. Baker ◽  
Dee Silver ◽  
C. Michael White ◽  
Jeffrey Kluger ◽  
Jeffrey Aberle ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Agonists ◽  
Meta Analysis ◽  
Early Parkinson’S Disease

scholarly journals A szelektív monoaminoxidáz-B-gátlók helye a Parkinson-kór kezelési stratégiájában a marosvásárhelyi ideggyógyászati klinikák gyakorlatában

2017 ◽  
Vol 158 (51) ◽  
pp. 2023-2028
Author(s):  
József Attila Szász ◽  
Viorelia Constantin ◽  
Péter Alpár Fazakas ◽  
Eszter Blényesi ◽  
Levente Gábor Grieb ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Dopamine Agonists ◽  
Disease Duration ◽  
Monoamine Oxidase Inhibitors ◽  
Monoamine Oxidase B ◽  
Advanced Stages ◽  
Therapeutic Recommendations

Abstract: Introduction: Selective monoamine oxidase B inhibitors have an accurate place in therapeutical strategy of Parkinsons’s disease. In the early stages of the disease, especially in younger patients with milder symptoms, the introduction of levodopa substitution could be efficacious in delaying; in advanced stages they are mainly used to treat motor complications, as an adjunct to levodopa. Aim: The evaluation of therapeutical strategies used in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital in order to define the role of monoamine oxidase B inhibitors. Method: This retrospective study includes all records of patients with Parkinson’s disease hospitalized between 1 January 2003 and 31 December 2016. From the 2194 reports we used data focusing on the therapeutic recommendations. Regarding disease duration, we divided the patients in two groups: less than or equal to 5 years and more than 5 years. Results: From the 1183 patients in first group, 243 received monoamine oxidase inhibitors: 12 as monotherapy, 52 together with dopamine agonists, in 61 cases combined with levodopa. In 118 cases monoamine oxidase inhibitors were combined with levodopa and dopamine agonists. From 582 cases whith Parkinson’s disease for more than 5 years, 195 received monoamine oxidase B inhibitors (selegiline: 10 cases, rasagiline: 185 cases). In 429 cases we did not find accurate data regarding disease duration (selegiline: 5 cases, rasagiline: 93 cases). Conclusion: The use of monoamine oxidase B inhibitors was similar to those found in literature. The treating physicians should utilise more confidently the available therapeutical combinations. Orv Hetil. 2017; 158(51): 2023–2028.

scholarly journals Role of Corpus Callosum Volumetry in Differentiating the Subtypes of Progressive Supranuclear Palsy and Early Parkinson's Disease

2017 ◽  
Vol 4 (4) ◽  
pp. 552-558 ◽  
Author(s):  
Abhishek Lenka ◽  
Shaik Afsar Pasha ◽  
Sandhya Mangalore ◽  
Lija George ◽  
Ketan Ramakant Jhunjhunwala ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Corpus Callosum ◽  
Progressive Supranuclear Palsy ◽  
Early Parkinson’S Disease

scholarly journals The Role of Vitamin D in Disease Progression in Early Parkinson’s Disease

2017 ◽  
Vol 7 (4) ◽  
pp. 669-675 ◽  
Author(s):  
Isobel Sleeman ◽  
Terry Aspray ◽  
Rachael Lawson ◽  
Shirley Coleman ◽  
Gordon Duncan ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease ◽  
Disease Progression ◽  
Early Parkinson’S Disease
Sign in / Sign up

Export Citation Format

Share Document